{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-034263","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.066198+00:00","generated_at":"2026-05-16T21:17:08.779305+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Moleculin Biotech Enters Research Agreement with UNC to Evaluate Annamycin for Pancreatic Cancer","bullets":["Agreement with University of North Carolina at Chapel Hill for investigator-initiated preclinical research on Annamycin for pancreatic cancer.","Moleculin will supply Annamycin; studies will evaluate liposomal Annamycin vs. Doxil in PDAC GEMM models.","CEO Walter Klemp noted Annamycin's high affinity for pancreas and correlation of topoisomerase II upregulation with poor survival.","Preclinical research is grant-funded and dovetails with recently announced investigator-funded clinical trial in pancreatic cancer patients.","Annamycin has Fast Track Status and Orphan Drug Designations from FDA for AML and STS lung mets, and EMA for relapsed/refractory AML."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-034263","json":"https://secwatch.observer/filing/0001437749-25-034263.json","markdown":"https://secwatch.observer/filing/0001437749-25-034263.md","text":"https://secwatch.observer/filing/0001437749-25-034263.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774925034263/0001437749-25-034263-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774925034263/mbrx20251110_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-16T21:17:08.779305+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}